| (Values in U.S. Thousands) | Sep, 2023 | Sep, 2022 | Sep, 2021 | Sep, 2020 | Sep, 2019 |
| Sales | 4,202 | 18,690 | 10,035 | 5,685 | 3,131 |
| Sales Growth | -77.52% | +86.25% | +76.52% | +81.57% | +2,327.13% |
| Net Income | -33,156 | -18,005 | -21,576 | -9,213 | -4,318 |
| Net Income Growth | -84.15% | +16.55% | -134.19% | -113.36% | +51.18% |
Redx Pharma Plc (REDX.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Redx Pharma PLC is a United Kingdom-based biotechnology company focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases. Its product pipeline under development includes Porcupine Inhibitor, ROCK2 Selective Inhibitor, GI-targeted ROCK inhibitor, Pan-RAF Inhibitor, and others. The firm operates geographically in the UK and Ireland. Revenue is generated from; Scientific programmes and research collaboration, Research collaboration, and Research and preclinical development services.
Fiscal Year End Date: 09/30